DUBLIN, Ireland, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will host an investor call on Wednesday, January 31 at 8:30 AM ET to provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Wednesday, January 31, 2024 |
| Time: | 8:30 AM ET |
| United States: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13744109 |
| Webcast: | Click Here for Webcast |
| CallMe™: | Click Here for CallMe Feature |
About Trinity Biotech
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc Des Fitzgerald (353)-1-2769800 | LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.09 |
| Daily Change: | -0.06 -5.22 |
| Daily Volume: | 87,700 |
| Market Cap: | US$10.320M |
September 24, 2024 September 09, 2024 August 26, 2024 August 14, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
